Daniela Marasco Selected Research

Nucleophosmin

10/2022	Small molecules enhancers of amyloid aggregation of C-terminal domain of Nucleophosmin 1 in acute myeloid leukemia.
1/2022	Type C mutation of nucleophosmin 1 acute myeloid leukemia: Consequences of intrinsic disorder.
10/2021	Type F mutation of nucleophosmin 1 Acute Myeloid Leukemia: A tale of disorder and aggregation.
1/2021	Conformational consequences of NPM1 rare mutations: An aggregation perspective in Acute Myeloid Leukemia.
12/2020	Proteostasis unbalance of nucleophosmin 1 in Acute Myeloid Leukemia: An aggregomic perspective.
1/2020	Cleavage of the APE1 N-Terminal Domain in Acute Myeloid Leukemia Cells Is Associated with Proteasomal Activity.
2/2019	Amyloid fibers deriving from the aromatic core of C-terminal domain of nucleophosmin 1.
1/2019	The acute myeloid leukemia-associated Nucleophosmin 1 gene mutations dictate amyloidogenicity of the C-terminal domain.
1/2019	Structural insights into amyloid structures of the C-terminal region of nucleophosmin 1 in type A mutation of acute myeloid leukemia.
2/2017	Insights into amyloid-like aggregation of H2 region of the C-terminal domain of nucleophosmin.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniela Marasco Research Topics

Disease

29	Neoplasms (Cancer) 10/2022 - 12/2008
13	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 01/2013
8	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2022 - 01/2013
7	Inflammation (Inflammations) 04/2022 - 12/2008
7	Neuroblastoma 03/2021 - 09/2015
6	Nervous System Diseases (Neurological Disorders) 08/2020 - 01/2016
4	Alzheimer Disease (Alzheimer's Disease) 02/2022 - 02/2007
4	Infections 06/2020 - 07/2011
4	Neoplasm Metastasis (Metastasis) 01/2019 - 12/2008
4	Type 2 Diabetes Mellitus (MODY) 05/2011 - 06/2008
3	Atherosclerosis 08/2020 - 11/2014
3	Triple Negative Breast Neoplasms 05/2020 - 07/2012
3	Breast Neoplasms (Breast Cancer) 01/2019 - 02/2010
3	Genomic Instability 05/2016 - 04/2008
3	Autoimmune Diseases (Autoimmune Disease) 01/2016 - 07/2005
3	Insulin Resistance 05/2011 - 08/2008
2	Tuberculosis (Tuberculoses) 06/2020 - 07/2014
2	Wounds and Injuries (Trauma) 01/2019 - 07/2014
2	Multiple Sclerosis 04/2017 - 01/2016
2	Parkinson Disease (Parkinson's Disease) 01/2016 - 08/2010
2	Amyloid Plaque 01/2013 - 02/2007
1	Atherosclerotic Plaque (Atheroma) 08/2020
1	COVID-19 01/2020
1	Hepatocellular Carcinoma (Hepatoma) 01/2020
1	Hypersensitivity (Allergy) 01/2019
1	Melanoma (Melanoma, Malignant) 04/2017
1	Prostatic Neoplasms (Prostate Cancer) 09/2016
1	Carcinoma (Carcinomatosis) 05/2016
1	Hypertension (High Blood Pressure) 01/2016
1	Stroke (Strokes) 01/2016
1	Huntington Disease (Huntington's Disease) 01/2016
1	Carcinogenesis 02/2014
1	Glioblastoma (Glioblastoma Multiforme) 01/2014
1	Pulmonary Arterial Hypertension 01/2014
1	Skin Diseases (Skin Disease) 07/2013
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 01/2013

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 10/2022 - 04/2008
15	Peptides (Polypeptides)IBA 02/2022 - 07/2005
13	NucleophosminIBA 10/2022 - 09/2015
9	Amyloid (Amyloid Fibrils)IBA 10/2022 - 02/2017
6	CytokinesIBA 04/2022 - 01/2014
6	Pharmaceutical PreparationsIBA 06/2020 - 06/2016
6	EphA2 ReceptorIBA 01/2020 - 03/2012
4	LipidsIBA 08/2020 - 11/2014
4	Biological ProductsIBA 05/2020 - 09/2015
4	CannabinoidsIBA 04/2017 - 01/2016
4	EndonucleasesIBA 05/2016 - 07/2012
3	PeptidomimeticsIBA 08/2020 - 01/2016
3	EndocannabinoidsIBA 06/2016 - 01/2016
3	PhosphoproteinsIBA 05/2011 - 08/2008
3	phospholipase D1IBA 05/2011 - 08/2008
2	Suppressor of Cytokine Signaling 3 ProteinIBA 04/2022 - 05/2020
2	MetalsIBA 03/2021 - 06/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 06/2020 - 01/2019
2	Mitochondrial Precursor Protein Import Complex ProteinsIBA 10/2018 - 12/2017
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 12/2017 - 11/2014
2	Interleukin-22 (IL-22)IBA 07/2017 - 04/2017
2	Prion ProteinsIBA 01/2013 - 02/2007
2	Insulin (Novolin)FDA Link 10/2010 - 02/2010
2	Amyloid beta-PeptidesIBA 02/2009 - 02/2007
1	GlycoconjugatesIBA 02/2022
1	Nuclear Proteins (Protein, Nuclear)IBA 12/2020
1	Janus KinasesIBA 08/2020
1	NADPH Oxidases (NAD(P)H oxidase)IBA 08/2020
1	AntioxidantsIBA 08/2020
1	Coordination ComplexesIBA 06/2020
1	VaccinesIBA 01/2020
1	Amyloidogenic ProteinsIBA 01/2020
1	Erythropoietin FDA Link 01/2020
1	Penicillins (Penicillin)FDA Link 01/2019
1	Fibronectins (Fibronectin)IBA 01/2019
1	Phenobarbital (Luminal)FDA Link 01/2019
1	Erythromycin (Erycette)FDA LinkGeneric 01/2019
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2019
1	CollagenIBA 01/2019
1	HydrocarbonsIBA 10/2018
1	Therapeutic UsesIBA 09/2018
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 09/2018
1	Cisplatin (Platino)FDA LinkGeneric 10/2017
1	LigandsIBA 09/2017
1	Ephrin-A2 (Ephrin A2)IBA 09/2017
1	Interleukin-10 (Interleukin 10)IBA 07/2017
1	CB2 Cannabinoid ReceptorIBA 04/2017
1	Intrinsically Disordered ProteinsIBA 09/2016
1	liposomal doxorubicin (Doxil)FDA Link 05/2016
1	Saline SolutionIBA 05/2016
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2016
1	BromidesIBA 09/2015
1	EnzymesIBA 07/2014
1	OxysterolsIBA 07/2014
1	ApolipoproteinsIBA 07/2014
1	EstersIBA 07/2014
1	Penicillin-Binding Proteins (Penicillin-Binding Protein)IBA 07/2014
1	Sirtuin 1IBA 02/2014
1	IntegrinsIBA 01/2014
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014
1	PS 5 (PS-5)IBA 07/2013
1	PrionsIBA 01/2013

Therapy/Procedure

10	Therapeutics 08/2020 - 08/2010
1	Role Playing (Playing, Role) 01/2019